IQGAP3 Promotes EGFR-ERK Signaling and the Growth and Metastasis of Lung Cancer Cells

Proteins of the IQGAP family display complicated and often contradictory activities in tumorigenesis. IQGAP1 has well documented oncogenic potential and IQGAP2 has putative tumor-suppressive function. IQGAP3 is the latest addition to this family and its role in cancer development remains to be defined. Here we demonstrate IQGAP3 expression is markedly increased in lung cancer tissues at both mRNA and protein levels. Overexpression of IQGAP3 promoted tumor cell growth, and migration and invasion, whereas knockdown of IQGAP3 exhibited opposite effects. Moreover, suppression of IQGAP3 in a lung cancer cell line caused a reduction in the tumorigenicity of these cells in lung tissue after intravenous injection. Furthermore, we showed that IQGAP3 is able to interact with ERK1 and enhance its phosphorylation following treatment with EGF. These data suggest that IQGAP3 may contribute to the pathogenesis of lung cancer by modulating EGFR-ERK signaling.

[1]  J. Settleman,et al.  Identification of a human rasGAP-related protein containing calmodulin-binding motifs. , 1994, The Journal of biological chemistry.

[2]  A. Levitzki.  EGF receptor as a therapeutic target. , 2003, Lung cancer.

[3]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[4]  Manisha Sharma,et al.  IQGAP1 regulation and roles in cancer. , 2009, Cellular signalling.

[5]  Hisashi Nojima,et al.  IQGAP3 regulates cell proliferation through the Ras/ERK signalling cascade , 2008, Nature Cell Biology.

[6]  A. Adjei,et al.  Novel targets for lung cancer therapy: part II. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Hung,et al.  Nuclear trafficking of the epidermal growth factor receptor family membrane proteins , 2010, Oncogene.

[8]  P. Ji,et al.  The EPHB6 Receptor Tyrosine Kinase Is a Metastasis Suppressor That Is Frequently Silenced by Promoter DNA Hypermethylation in Non–Small Cell Lung Cancer , 2010, Clinical Cancer Research.

[9]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[10]  K. Takeuchi,et al.  EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR‐targeting tyrosine kinase inhibitors , 2010, The FEBS journal.

[11]  N. Reinmuth,et al.  Signal transduction pathways as novel therapy targets in lung cancer. , 2004, Lung cancer.

[12]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[13]  A. Sajantila,et al.  DNA copy number aberrations in intestinal-type gastric cancer revealed by array-based comparative genomic hybridization. , 2006, Cancer genetics and cytogenetics.

[14]  P. Granone,et al.  EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation , 2013, International journal of medical sciences.

[15]  D. Sacks,et al.  IQGAP proteins are integral components of cytoskeletal regulation , 2003, EMBO reports.

[16]  D. Sacks,et al.  IQGAP1 in cellular signaling: bridging the GAP. , 2006, Trends in cell biology.

[17]  D. Church,et al.  The Ras GTPase-activating-protein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases , 1996, Molecular and cellular biology.

[18]  Tong Chuan.  The Association of Thoracic and Cardiovascular Surgeons of Asia , 1993 .

[19]  Keith M. Kerr,et al.  Gene Expression Profiling in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[20]  Sakari Knuutila,et al.  Clustering of molecular alterations in gastroesophageal carcinomas. , 2004, Neoplasia.

[21]  国本 晃司.  Involvement of IQGAP3, a regulator of Ras/ERK-related cascade, in hepatocyte proliferation in mouse liver regeneration and development , 2010 .

[22]  David B Sacks,et al.  IQGAP1 and its binding proteins control diverse biological functions. , 2012, Cellular signalling.

[23]  A. Adjei,et al.  Novel targets for lung cancer therapy: part I. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Wei Zhao,et al.  An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. , 2012, Cancer research.

[25]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[26]  N. Normanno,et al.  Epidermal growth factor receptor (EGFR) signaling in cancer. , 2006, Gene.

[27]  Liquid Biopsies.  Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.

[28]  D. Sacks,et al.  IQGAP1 in microbial pathogenesis: Targeting the actin cytoskeleton , 2011, FEBS letters.

[29]  W. Bahou,et al.  Development of Hepatocellular Carcinoma in Iqgap2-Deficient Mice Is IQGAP1 Dependent , 2008, Molecular and Cellular Biology.

[30]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[31]  K. Kaibuchi,et al.  IQGAP3, a novel effector of Rac1 and Cdc42, regulates neurite outgrowth , 2007, Journal of Cell Science.

[32]  T. Veenstra,et al.  Sulfiredoxin–Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling , 2011, Proceedings of the National Academy of Sciences.

[33]  K. Kaibuchi,et al.  IQGAP1: a key regulator of adhesion and migration , 2005, Journal of Cell Science.

[34]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[35]  Shadan Ali,et al.  Up-Regulation of Sonic Hedgehog Contributes to TGF-β1-Induced Epithelial to Mesenchymal Transition in NSCLC Cells , 2011, PloS one.

[36]  R. Trojanec,et al.  Non-small cell lung cancer--genetic predictors. , 2013, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[37]  Michael R Hamblin,et al.  CA : A Cancer Journal for Clinicians , 2011 .

[38]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[39]  I. Beavon.  The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. , 2000, European journal of cancer.

[40]  Y. Yarden.  The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[41]  Jun Zhang,et al.  Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma. , 2011, European journal of cancer.

[42]  F. Hirsch,et al.  The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. , 2002, Lung cancer.

[43]  B. Yalcin,et al.  Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.

[44]  Houwen Li.  State of the art:lung cancer in China. , 2003, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[45]  A. Ridley,et al.  IQGAP1 Promotes Cell Motility and Invasion* , 2003, Journal of Biological Chemistry.

[46]  L. Hawthorn,et al.  Integration of transcript expression, copy number and LOH analysis of infiltrating ductal carcinoma of the breast , 2010, BMC Cancer.

[47]  Ha-won Jeong,et al.  IQGAP1 Binds Rap1 and Modulates Its Activity* , 2004, Journal of Biological Chemistry.

[48]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[49]  A. Mazo,et al.  p16Ink4a overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors , 2011, Oncogene.

[50]  D. Sacks,et al.  IQGAP1 as signal integrator: Ca2+, calmodulin, Cdc42 and the cytoskeleton , 2003, FEBS letters.

[51]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.